Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00241_DB00321_nanopub.RA7BqOg77sIgkVnsh3QfTyhd0_CAyxrN6_4s23sAigz7M#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00241_DB00321 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00241_DB00321 label "DDI between Butalbital and Amitriptyline - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. [drugbank_resource:DB00241_DB00321]" assertion.
- drugbank_resource:DB00241_DB00321 identifier "drugbank_resource:DB00241_DB00321" assertion.
- drugbank_resource:DB00241_DB00321 title "DDI between Butalbital and Amitriptyline - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation." assertion.
- drugbank:DB00321 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB00321 assertion.
- drugbank:DB00241 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB00321 assertion.